DE60121096D1 - Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden - Google Patents

Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden

Info

Publication number
DE60121096D1
DE60121096D1 DE60121096T DE60121096T DE60121096D1 DE 60121096 D1 DE60121096 D1 DE 60121096D1 DE 60121096 T DE60121096 T DE 60121096T DE 60121096 T DE60121096 T DE 60121096T DE 60121096 D1 DE60121096 D1 DE 60121096D1
Authority
DE
Germany
Prior art keywords
receptor ligand
neurotensin receptor
obesity
treatment
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60121096T
Other languages
English (en)
Other versions
DE60121096T2 (de
Inventor
John Richard Neville Hadcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22739686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60121096(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60121096D1 publication Critical patent/DE60121096D1/de
Application granted granted Critical
Publication of DE60121096T2 publication Critical patent/DE60121096T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60121096T 2000-04-27 2001-04-27 Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden Revoked DE60121096T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19995100P 2000-04-27 2000-04-27
US199951 2000-04-27

Publications (2)

Publication Number Publication Date
DE60121096D1 true DE60121096D1 (de) 2006-08-10
DE60121096T2 DE60121096T2 (de) 2006-12-07

Family

ID=22739686

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121096T Revoked DE60121096T2 (de) 2000-04-27 2001-04-27 Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden

Country Status (13)

Country Link
US (1) US6699832B2 (de)
EP (1) EP1157695B1 (de)
JP (1) JP2002275092A (de)
KR (1) KR20010098829A (de)
AT (1) ATE331518T1 (de)
AU (1) AU3888801A (de)
CA (1) CA2345180A1 (de)
DE (1) DE60121096T2 (de)
ES (1) ES2264679T3 (de)
HU (1) HUP0101666A3 (de)
IL (1) IL142707A0 (de)
NZ (1) NZ511354A (de)
ZA (1) ZA200103365B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US6693130B2 (en) * 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
EP1370268B1 (de) * 2001-03-23 2009-07-15 Corcept Therapeutics, Inc. Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
DE60230818D1 (de) * 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
BR0308904A (pt) * 2002-04-10 2005-05-03 Lilly Co Eli Método de tratamento de gastroparesia, e, uso de um composto de glp-1
WO2003093829A1 (en) * 2002-05-02 2003-11-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neurotensin receptor 2 (nt2)
AU2003229736A1 (en) * 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1)
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
US8066997B2 (en) * 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
LT3225251T (lt) * 2006-12-21 2020-04-10 H. Lundbeck A/S Proneurotrofinų veiklos moduliavimas
WO2009033808A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US8476221B2 (en) * 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
WO2014071128A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Macrophage-derived matrix vesicles: an alternative mechanism for microcalcification in atherosclerotic plaques
SI3380495T1 (sl) * 2015-11-24 2022-01-31 Transfert Plus, S.E.C. Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo
US10473670B2 (en) * 2016-02-25 2019-11-12 University Of Kentucky Research Foundation Method of predicting obesity comprising measuring neurotensin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US5217953A (en) 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5250558A (en) 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2760750B1 (fr) 1997-03-17 1999-05-28 Sanofi Sa Recepteur humain a la neurotensine de type 2(hnt-r2)
US6008050A (en) 1997-04-02 1999-12-28 Smithkline Beecham Corporation Human neurotensin receptor type 2 and splice variants thereof
US6274720B1 (en) * 1997-12-31 2001-08-14 Incyte Genomics, Inc. Human preproneurotensin/neuromedin N
US6420137B1 (en) 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor

Also Published As

Publication number Publication date
NZ511354A (en) 2003-03-28
ATE331518T1 (de) 2006-07-15
KR20010098829A (ko) 2001-11-08
JP2002275092A (ja) 2002-09-25
HU0101666D0 (en) 2001-06-28
CA2345180A1 (en) 2001-10-27
HUP0101666A2 (hu) 2002-02-28
US6699832B2 (en) 2004-03-02
DE60121096T2 (de) 2006-12-07
IL142707A0 (en) 2002-03-10
ZA200103365B (en) 2002-10-25
EP1157695A1 (de) 2001-11-28
AU3888801A (en) 2001-11-01
EP1157695B1 (de) 2006-06-28
HUP0101666A3 (en) 2003-03-28
ES2264679T3 (es) 2007-01-16
US20010046956A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE60121096D1 (de) Methode zur Behandlung von Fettsucht anhand eines Neurotensinreceptor-Liganden
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE60239612D1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
ME02785B (me) Humana anti-ngf neutrališuća antitela kao selektivni inhibitori ngf signalnog puta
ATE456580T1 (de) Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonisten
ATE375999T1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
WO2004009064A8 (de) Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE462699T1 (de) Substituierte 4,5,6,7-tetrahydro-benzothiazol-2- ylamin-verbindungen
ATE506947T1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
WO2006002022A3 (en) Compositions and methods useful for the treatment of hyperglycemia
DE60045750D1 (de) E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE60143390D1 (de) Methode zur behandlung von herzinsuffizienz
ATE431157T1 (de) Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
DK1366033T3 (da) Kemiske forbindelser
DE60228408D1 (de) Gssp4-polynukleotide und -polypeptide sowie deren verwendung
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
ATE528065T1 (de) Verfahren zur vermeidung des verstopfens von filtrationsmembranen
WO2004026102A3 (en) Treatment of schizophrenia

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation